AS01B adjuvant mechanisms and CD4 T cell responses

Abstract

AS01B adjuvant induces CD4 T cell responses through a two-phase mechanism involving initial transient inflammatory activation followed by sustained IFN-signaling pathway engagement. Studies demonstrate that AS01B triggers early innate responses including IL-6 and CRP peaking at 24 hours post-vaccination, followed by IFN-γ upregulation and activation of IFN-inducible genes (STAT1, IRF1, MX1, CXCL10) after the second dose. This innate activation directly correlates with enhanced CD4+ T cell outcomes, as multi-parametric modeling shows associations between CRP, IL-6, IFN-signaling pathway activation and subsequent CD4 responses. AS01B consistently induces superior CD4 T cell responses compared to AS02A (3.1-fold higher frequencies), AS03 (5.4-fold higher), AS04 (2.8-fold higher), and aluminum adjuvants, with exceptional durability extending 18-36+ months post-vaccination.

The CD4 response polarization induced by AS01B is context-dependent rather than fixed. Protein/AS01B formulations activate PPAR, FcεRI, and TGF-β pathways, inducing Th2/Tfh2-biased responses that correlate with enhanced antibody production and memory B cell frequencies. In contrast, most other AS01B formulations primarily activate IFN-signaling pathways, driving strong Th1 responses characterized by high IFN-γ production. AS01B’s superiority depends on both liposomal delivery and optimal component dosing, as AS01E containing half the MPL/QS-21 produces comparable innate profiles but 2.2-fold lower CD4 responses. The synergistic combination of MPL and QS-21 in liposomes appears critical for maximal CD4 activation.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question. More on methods

Paper search

We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of Semantic Scholar and OpenAlex.

We ran this query: “AS01B adjuvant mechanisms and CD4 T cell responses”

The search returned 200 total results from Elicit. We retrieved 200 papers most relevant to the query for screening.

Screening

We screened in sources based on their abstracts that met these criteria:

• AS01B Adjuvant Focus: Investigates AS01B adjuvant specifically (containing MPL and QS-21 in liposomes)?
• CD4 T Cell Response Measurement: Measures CD4 T cell responses as primary or secondary outcomes?
• Appropriate Study Type: Human clinical trial or animal study using established laboratory models?
• AS01B Data Availability: Includes AS01B data?
• CD4 T Cell Data Inclusion: Includes CD4 T cell data?
• CD4 T Cell Response Focus: Includes CD4 T cell response data?
• AS01B Effect Attribution: Can AS01B effects be isolated in this study?
• Full Publication Status: Is this a full-text publication?

CD4 Responses

We extracted all CD4 T cell response data for AS01B, including:

• CD4 T cell proliferation or activation markers
• Cytokine production by CD4 cells
• CD4 T cell counts or frequencies
• Functional assays
• Persistence/durability of CD4 responses
• Any CD4 subset analysis

Comparative adjuvant effects

AS01B demonstrated superior CD4 T cell induction compared to all tested adjuvants. In a comprehensive comparison, AS01B induced CD4 T cell responses 5.4-fold greater than AS03, 2.8-fold greater than AS04, and 2.2-fold greater than AS01E (p<0.001 for all comparisons).

Mechanistic links between AS01B activation and CD4 T cell responses

Burny et al. established connections between AS01B’s innate mechanisms and CD4 outcomes through multi-parametric modeling. Increased IFN-γ levels after the second injection correlated with enhanced CD4+ T-cell responses. The authors suggested “trained immunity” as a mechanism linking innate responses to sustained CD4+ T-cell responses.

Synthesis

The evidence reveals AS01B functions through a two-phase mechanism linking innate activation to durable CD4 responses. The Th1/Th2 skewing appears platform-dependent rather than contradictory, enhancing vaccine immunogenicity through complementary mechanisms for cellular immunity and antibody production.